# R-DHAP vs POLA-R-DHAP Followed by Autologous Transplant as First Salvage Treatment in Patient With Relapsed or Refractory Diffuse Large B Cell Lymphoma

> **NCT05966233** · PHASE2 · WITHDRAWN · sponsor: **Fondazione Italiana Linfomi - ETS**

## Conditions studied

- Diffuse Large B Cell Lymphoma Refractory
- Diffuse Large B-cell Lymphoma Recurrent

## Interventions

- **DRUG:** R-DHAP
- **DRUG:** Pola-R-DHAP

## Key facts

- **NCT ID:** NCT05966233
- **Lead sponsor:** Fondazione Italiana Linfomi - ETS
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2024-01
- **Primary completion:** 2029-01
- **Final completion:** 2029-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Sponsor decision
- **Last updated:** 2024-05-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05966233

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05966233, "R-DHAP vs POLA-R-DHAP Followed by Autologous Transplant as First Salvage Treatment in Patient With Relapsed or Refractory Diffuse Large B Cell Lymphoma". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT05966233. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*